目的建立儿童发育性髋关节发育不良(developmental dysplasia of the hip,DDH)闭合复位术后结局预测模型,并利用该模型指导DDH闭合复位术后残余髋臼发育不良(residual acetabulalr dysplasia,RAD)手术时机的选择。方法回顾性分析国内多...目的建立儿童发育性髋关节发育不良(developmental dysplasia of the hip,DDH)闭合复位术后结局预测模型,并利用该模型指导DDH闭合复位术后残余髋臼发育不良(residual acetabulalr dysplasia,RAD)手术时机的选择。方法回顾性分析国内多个医疗中心2004-2015年采用闭合复位术治疗的449例(522髋)DDH患儿临床资料,患儿年龄(16.3±5.1)个月。术前在骨盆正位X线片上评估脱位程度的国际髋关节发育不良协会(International Hip Dysplasia Institute,IHDI)分型、股骨头骨化核以及髋臼指数(acetabular index,AI)。术后测量第1、2、3、4年及末次随访时的AI、中心边缘角(centre-edge angle of Wiberg,CEA)和Reimer指数(Reimer's index,RI),评估股骨头缺血性坏死(avascular necrosis of the femoral head,AVN)情况。根据末次随访时Severin影像学评级以及是否接受二期骨盆截骨术,将患儿分成两组:SeverinⅠ、Ⅱ级为痊愈组,SeverinⅢ、Ⅳ级或接受了骨盆截骨术者为RAD组。利用Cox回归构建DDH闭合复位术后痊愈预测模型,并用受试者操作特征(receiver operating characteristic,ROC)曲线进行内部验证。结果522髋中,IHDI分型为Ⅱ型70髋(13.4%),Ⅲ型223髋(44.6%),Ⅳ型219髋(42%)。复位前410髋(78.5%)已出现股骨头骨化核。总体AVN(Ⅱ型以上)发生率为12.8%。痊愈组329髋(63%),痊愈时间(33.3±14.7)个月(8.4~111.4个月),93.6%(308/329)的痊愈患儿痊愈时间在术后5年以内。Cox回归分析显示,IHDI分型、股骨头骨化核、复位年龄、当前AI、CEA、RI、AVN是DDH闭合复位术后累积痊愈概率的影响因素,利用上述影响因素,本研究成功构建了DDH闭合复位术后痊愈预测模型。该模型中所有因素的总分为-11~17分,对应痊愈概率为0.02~1.0。在该模型下,ROC曲线分析显示,术后第1、2、3、4年总分小于2.5、1.5、2.5、1.5分时,患儿痊愈概率显著较高(81.4%~96.1%),ROC曲线下面积为0.808~0.910,Kappa系数为0.497~0.618。相反,当总分大于1.5~2.5分时,RAD发生率显著升高,建议行骨盆截骨术。结论本研究构建的痊愈预测模型可以有效预测RAD,并指导骨盆截骨手术时机的选择。在该模型下,如果术后第1、2、3、4年时模型中所有因素总分大于2.5、1.5、2.5、1.5分,则RAD发生率显著升高。展开更多
For the goals of security and privacy preservation,we propose a blind batch encryption-and public ledger-based data sharing protocol that allows the integrity of sensitive data to be audited by a public ledger and all...For the goals of security and privacy preservation,we propose a blind batch encryption-and public ledger-based data sharing protocol that allows the integrity of sensitive data to be audited by a public ledger and allows privacy information to be preserved.Data owners can tightly manage their data with efficient revocation and only grant one-time adaptive access for the fulfillment of the requester.We prove that our protocol is semanticallly secure,blind,and secure against oblivious requesters and malicious file keepers.We also provide security analysis in the context of four typical attacks.展开更多
In eukaryotic organisms,the most common internal modification of messenger RNA(m RNA)is N6-methyladenosine(m6A).This modification can be dynamically and reversibly controlled by specific enzymes known as m6A writers a...In eukaryotic organisms,the most common internal modification of messenger RNA(m RNA)is N6-methyladenosine(m6A).This modification can be dynamically and reversibly controlled by specific enzymes known as m6A writers and erasers.The fat-mass and obesity-associated protein(FTO)catalyzes RNA demethylation and plays a critical role in various physiological and pathological processes.Our research identified dynamic alterations in both m6A and FTO during the assembly of primordial follicles,with an inverse relationship observed for m6A levels and nuclear-localized FTO expression.Application of Fto small interfering RNA(si RNA)altered the expression of genes related to cell proliferation,hormone regulation,and cell chemotaxis,and affected RNA alternative splicing.Overexpression of the full-length Fto gene led to changes in m6A levels,alternative splicing of Cdk5,cell proliferation,cell cycle progression,and proportion of primordial follicles.Conversely,overexpression of Fto lacking a nuclear localization signal(NLS)did not significantly alter m6A levels or primordial follicle assembly.These findings suggest that FTO,localized in the nucleus but not in the cytoplasm,regulates RNA m6A demethylation and plays a role in cell proliferation,cell cycle progression,and primordial follicle assembly.These results highlight the potential of m6A and its eraser FTO as possible biomarkers and therapeutic targets.展开更多
BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,i...BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,it is unclear whether this combination is superior to chemotherapy alone.AIM To assess the comparative effectiveness and tolerability of combining PD-1 inhibitors with chemotherapy vs chemotherapy alone in patients with advanced gastric cancer,gastroesophageal junction(GEJ)cancer,or oesophageal carcinoma.METHODS We searched the PubMed and Embase databases for studies that compared the efficacy and tolerance of PD-1 inhibitors in combination with chemotherapy vs chemotherapy alone in patients with advanced oesophageal or gastric cancer.We employed either random or fixed models to analyze the outcomes of each clinical trial,en-compassing data on overall survival(OS),progression-free survival(PFS),objective response rate,and adverse events(AEs).RESULTS Nine phase 3 clinical trials(7016 advanced oesophageal and gastric cancer patients)met the inclusion criteria.Our meta-analysis demonstrated that the pooled PD-1 inhibitor+chemotherapy group had a significantly longer OS than the chemotherapy-alone group[hazard ratio(HR)=0.76,95%confidence interval(CI):0.71-0.81];the pooled PFS result was consistent with that of OS(HR=0.67,95%CI:0.61-0.74).The count of patients achieving an objective response in the PD-1 inhibitor+chemotherapy group surpassed that of the chemotherapy-alone group[odds ratio(OR)=1.86,95%CI:1.59-2.18].AE incidence was also higher in the combination-therapy group than in the chemotherapy-alone group,regardless of whether≥grade 3 only(OR=1.30,95%CI:1.07-1.57)or all AE grades(OR=1.88,95%CI:1.39-2.54)were examined.We performed a subgroup analysis based on the programmed death-ligand 1(PD-L1)combined positive score(CPS)and noted extended OS and PFS durations within the CPS≥1,CPS≥5,and CPS≥10 subgroups of the PD-1 inhibitor+chemotherapy group.CONCLUSION In contrast to chemotherapy alone,the combination of PD-1 inhibitor and chemotherapy appears to present a more favorable option for initial or subsequent treatment in patients with gastric cancer,GEJ tumor,or oesophageal cancer.This holds true particularly for individuals with PD-L1 CPS scores of≥5 and≥10.展开更多
AIM:To assess the clinical efficacy and safety of combining panretinal photocoagulation(PRP)with intravitreal conbercept(IVC)injections for patients with high-risk proliferative diabetic retinopathy(HR-PDR)complicated...AIM:To assess the clinical efficacy and safety of combining panretinal photocoagulation(PRP)with intravitreal conbercept(IVC)injections for patients with high-risk proliferative diabetic retinopathy(HR-PDR)complicated by mild or moderate vitreous hemorrhage(VH),with or without diabetic macular edema(DME).METHODS:Patients diagnosed with VH with/without DME secondary to HR-PDR and received PRP combined with IVC injections were recruited in this retrospective study.Upon establishing the patient’s diagnosis,an initial IVC was performed,followed by prompt administration of PRP.In cases who significant bleeding persisted and impeded the laser operation,IVC was sustained before supplementing with PRP.Following the completion of PRP,patients were meticulously monitored for a minimum of six months.Laser therapy and IVC injections were judiciously adjusted based on fundus fluorescein angiography(FFA)results.Therapeutic effect and the incidence of adverse events were observed.RESULTS:Out of 42 patients(74 eyes),29 were male and 13 were female,with a mean age of 59.17±12.74y(33-84y).The diabetic history was between 1wk and 26y,and the interval between the onset of visual symptoms and diagnosis of HR-PDR was 1wk-1y.The affected eye received 2.59±1.87(1-10)IVC injections and underwent 5.5±1.02(4-8)sessions of PRP.Of these,68 eyes received PRP following 1 IVC injection,5 eyes after 2 IVC injections,and 1 eye after 3 IVC injections.Complete absorption of VH was observed in all 74 eyes 5-50wk after initial treatment,with resolution of DME in 51 eyes 3-48wk after initial treatment.A newly developed epiretinal membrane was noted in one eye.Visual acuity significantly improved in 25 eyes.No complications such as glaucoma,retinal detachment,or endophthalmitis were reported.CONCLUSION:The study suggests that the combination of PRP with IVC injections is an effective and safe modality for treating diabetic VH in patients with HR-PDR.展开更多
The development of Intelligent Transportation Systems(ITS)is closely intertwined with the growth of every city,serving as a critical component of smart city construction.This paper provides a concise overview of the c...The development of Intelligent Transportation Systems(ITS)is closely intertwined with the growth of every city,serving as a critical component of smart city construction.This paper provides a concise overview of the concept and overall framework of smart transportation.It emphasizes the application of key technologies,including Traffic Element Identification and Perception,data mining,and Smart Transportation System Integration Technology,in the field.Furthermore,the paper elucidates the current practical applications of smart transportation,showcasing its advancements and implementations in real-world scenarios.展开更多
文摘目的建立儿童发育性髋关节发育不良(developmental dysplasia of the hip,DDH)闭合复位术后结局预测模型,并利用该模型指导DDH闭合复位术后残余髋臼发育不良(residual acetabulalr dysplasia,RAD)手术时机的选择。方法回顾性分析国内多个医疗中心2004-2015年采用闭合复位术治疗的449例(522髋)DDH患儿临床资料,患儿年龄(16.3±5.1)个月。术前在骨盆正位X线片上评估脱位程度的国际髋关节发育不良协会(International Hip Dysplasia Institute,IHDI)分型、股骨头骨化核以及髋臼指数(acetabular index,AI)。术后测量第1、2、3、4年及末次随访时的AI、中心边缘角(centre-edge angle of Wiberg,CEA)和Reimer指数(Reimer's index,RI),评估股骨头缺血性坏死(avascular necrosis of the femoral head,AVN)情况。根据末次随访时Severin影像学评级以及是否接受二期骨盆截骨术,将患儿分成两组:SeverinⅠ、Ⅱ级为痊愈组,SeverinⅢ、Ⅳ级或接受了骨盆截骨术者为RAD组。利用Cox回归构建DDH闭合复位术后痊愈预测模型,并用受试者操作特征(receiver operating characteristic,ROC)曲线进行内部验证。结果522髋中,IHDI分型为Ⅱ型70髋(13.4%),Ⅲ型223髋(44.6%),Ⅳ型219髋(42%)。复位前410髋(78.5%)已出现股骨头骨化核。总体AVN(Ⅱ型以上)发生率为12.8%。痊愈组329髋(63%),痊愈时间(33.3±14.7)个月(8.4~111.4个月),93.6%(308/329)的痊愈患儿痊愈时间在术后5年以内。Cox回归分析显示,IHDI分型、股骨头骨化核、复位年龄、当前AI、CEA、RI、AVN是DDH闭合复位术后累积痊愈概率的影响因素,利用上述影响因素,本研究成功构建了DDH闭合复位术后痊愈预测模型。该模型中所有因素的总分为-11~17分,对应痊愈概率为0.02~1.0。在该模型下,ROC曲线分析显示,术后第1、2、3、4年总分小于2.5、1.5、2.5、1.5分时,患儿痊愈概率显著较高(81.4%~96.1%),ROC曲线下面积为0.808~0.910,Kappa系数为0.497~0.618。相反,当总分大于1.5~2.5分时,RAD发生率显著升高,建议行骨盆截骨术。结论本研究构建的痊愈预测模型可以有效预测RAD,并指导骨盆截骨手术时机的选择。在该模型下,如果术后第1、2、3、4年时模型中所有因素总分大于2.5、1.5、2.5、1.5分,则RAD发生率显著升高。
基金partially supported by the National Natural Science Foundation of China under grant no.62372245the Foundation of Yunnan Key Laboratory of Blockchain Application Technology under Grant 202105AG070005+1 种基金in part by the Foundation of State Key Laboratory of Public Big Datain part by the Foundation of Key Laboratory of Computational Science and Application of Hainan Province under Grant JSKX202202。
文摘For the goals of security and privacy preservation,we propose a blind batch encryption-and public ledger-based data sharing protocol that allows the integrity of sensitive data to be audited by a public ledger and allows privacy information to be preserved.Data owners can tightly manage their data with efficient revocation and only grant one-time adaptive access for the fulfillment of the requester.We prove that our protocol is semanticallly secure,blind,and secure against oblivious requesters and malicious file keepers.We also provide security analysis in the context of four typical attacks.
基金supported by the Natural Science Foundation of Shandong Province,China (ZR2017MC033)National Key Research and Development Program of China (2023YFD1300504)Taishan Scholar Construction Foundation of Shandong Province,China (ts20190946)。
文摘In eukaryotic organisms,the most common internal modification of messenger RNA(m RNA)is N6-methyladenosine(m6A).This modification can be dynamically and reversibly controlled by specific enzymes known as m6A writers and erasers.The fat-mass and obesity-associated protein(FTO)catalyzes RNA demethylation and plays a critical role in various physiological and pathological processes.Our research identified dynamic alterations in both m6A and FTO during the assembly of primordial follicles,with an inverse relationship observed for m6A levels and nuclear-localized FTO expression.Application of Fto small interfering RNA(si RNA)altered the expression of genes related to cell proliferation,hormone regulation,and cell chemotaxis,and affected RNA alternative splicing.Overexpression of the full-length Fto gene led to changes in m6A levels,alternative splicing of Cdk5,cell proliferation,cell cycle progression,and proportion of primordial follicles.Conversely,overexpression of Fto lacking a nuclear localization signal(NLS)did not significantly alter m6A levels or primordial follicle assembly.These findings suggest that FTO,localized in the nucleus but not in the cytoplasm,regulates RNA m6A demethylation and plays a role in cell proliferation,cell cycle progression,and primordial follicle assembly.These results highlight the potential of m6A and its eraser FTO as possible biomarkers and therapeutic targets.
文摘BACKGROUND The combination of programmed cell death protein-1(PD-1)inhibitor and che-motherapy is approved as a standard first-or second-line treatment in patients with advanced oesophageal or gastric cancer.However,it is unclear whether this combination is superior to chemotherapy alone.AIM To assess the comparative effectiveness and tolerability of combining PD-1 inhibitors with chemotherapy vs chemotherapy alone in patients with advanced gastric cancer,gastroesophageal junction(GEJ)cancer,or oesophageal carcinoma.METHODS We searched the PubMed and Embase databases for studies that compared the efficacy and tolerance of PD-1 inhibitors in combination with chemotherapy vs chemotherapy alone in patients with advanced oesophageal or gastric cancer.We employed either random or fixed models to analyze the outcomes of each clinical trial,en-compassing data on overall survival(OS),progression-free survival(PFS),objective response rate,and adverse events(AEs).RESULTS Nine phase 3 clinical trials(7016 advanced oesophageal and gastric cancer patients)met the inclusion criteria.Our meta-analysis demonstrated that the pooled PD-1 inhibitor+chemotherapy group had a significantly longer OS than the chemotherapy-alone group[hazard ratio(HR)=0.76,95%confidence interval(CI):0.71-0.81];the pooled PFS result was consistent with that of OS(HR=0.67,95%CI:0.61-0.74).The count of patients achieving an objective response in the PD-1 inhibitor+chemotherapy group surpassed that of the chemotherapy-alone group[odds ratio(OR)=1.86,95%CI:1.59-2.18].AE incidence was also higher in the combination-therapy group than in the chemotherapy-alone group,regardless of whether≥grade 3 only(OR=1.30,95%CI:1.07-1.57)or all AE grades(OR=1.88,95%CI:1.39-2.54)were examined.We performed a subgroup analysis based on the programmed death-ligand 1(PD-L1)combined positive score(CPS)and noted extended OS and PFS durations within the CPS≥1,CPS≥5,and CPS≥10 subgroups of the PD-1 inhibitor+chemotherapy group.CONCLUSION In contrast to chemotherapy alone,the combination of PD-1 inhibitor and chemotherapy appears to present a more favorable option for initial or subsequent treatment in patients with gastric cancer,GEJ tumor,or oesophageal cancer.This holds true particularly for individuals with PD-L1 CPS scores of≥5 and≥10.
基金Supported by Research Grants from the fund of Suzhou Kowloon Hospital(No.SZJL202106).
文摘AIM:To assess the clinical efficacy and safety of combining panretinal photocoagulation(PRP)with intravitreal conbercept(IVC)injections for patients with high-risk proliferative diabetic retinopathy(HR-PDR)complicated by mild or moderate vitreous hemorrhage(VH),with or without diabetic macular edema(DME).METHODS:Patients diagnosed with VH with/without DME secondary to HR-PDR and received PRP combined with IVC injections were recruited in this retrospective study.Upon establishing the patient’s diagnosis,an initial IVC was performed,followed by prompt administration of PRP.In cases who significant bleeding persisted and impeded the laser operation,IVC was sustained before supplementing with PRP.Following the completion of PRP,patients were meticulously monitored for a minimum of six months.Laser therapy and IVC injections were judiciously adjusted based on fundus fluorescein angiography(FFA)results.Therapeutic effect and the incidence of adverse events were observed.RESULTS:Out of 42 patients(74 eyes),29 were male and 13 were female,with a mean age of 59.17±12.74y(33-84y).The diabetic history was between 1wk and 26y,and the interval between the onset of visual symptoms and diagnosis of HR-PDR was 1wk-1y.The affected eye received 2.59±1.87(1-10)IVC injections and underwent 5.5±1.02(4-8)sessions of PRP.Of these,68 eyes received PRP following 1 IVC injection,5 eyes after 2 IVC injections,and 1 eye after 3 IVC injections.Complete absorption of VH was observed in all 74 eyes 5-50wk after initial treatment,with resolution of DME in 51 eyes 3-48wk after initial treatment.A newly developed epiretinal membrane was noted in one eye.Visual acuity significantly improved in 25 eyes.No complications such as glaucoma,retinal detachment,or endophthalmitis were reported.CONCLUSION:The study suggests that the combination of PRP with IVC injections is an effective and safe modality for treating diabetic VH in patients with HR-PDR.
文摘The development of Intelligent Transportation Systems(ITS)is closely intertwined with the growth of every city,serving as a critical component of smart city construction.This paper provides a concise overview of the concept and overall framework of smart transportation.It emphasizes the application of key technologies,including Traffic Element Identification and Perception,data mining,and Smart Transportation System Integration Technology,in the field.Furthermore,the paper elucidates the current practical applications of smart transportation,showcasing its advancements and implementations in real-world scenarios.
基金Supported by Grants from the Innovation Fund for Technology Based Firms of the Ministry of Science and Technology of the China,No.12C26215115999(in part)Special Fund on Industrial Revitalization and Transformation of the National Development and Reform Commission of the ChinaJinshan Science and Technology Co.Ltd,Chongqing,China
文摘AIM: To investigate the feasibility and safety of pH capsule to monitor pH in patients with gastroesophageal reflux disease (GERD).
